Akura Medical just locked in a Series C first close that lands with the weight of intention. $53M led by Qatar Investment Authority is not passive capital. That is conviction money from an investor that has no interest in small games, especially when the problem on the table hits roughly 900k patients in the U.S. every year and claims up to 100k lives. Venous thromboembolism does not negotiate, which is why the origin story matters here. Akura Medical was built inside the Shifamed engine created by Amr Salahieh, and the company carries that DNA through every piece of its technology. Add the technical firepower of Aadel Al-Jadda, and suddenly the name Akura feels less like branding and more like a blade designed for the work ahead.
The Katana Thrombectomy System amplifies that energy. While the current landscape of mechanical thrombectomy still forces physicians to fight through catheter clogging, long procedures, and instruments that feel more analog than the moment demands, the Katana system arrives with bi-directional low profile navigation, high velocity saline jets, real-time hemodynamic feedback, and the Sentinel console that removes the guesswork physicians have tolerated for far too long. It is engineered for clots of every texture, built to engage without crossing, and tuned for the single-pass efficiency that specialists want but rarely get. It is the kind of system that feels like it was designed by people who have spent 20+ years listening to every frustration in the cath lab.
What makes this raise compelling is that it follows proof rather than promises. Akura Medical began its first in human work in the Republic of Georgia in early 2023 and produced clean early results. The FDA granted IDE approval in late 2024 for the QUADRA-PE pivotal trial, a 118-patient global study now underway. The first enrollment landed at TriStar Centennial Medical Center with Dr. Samuel Horr performing the procedure, supported by co principal investigators Dr. Sanjum Sethi and Dr. Ann Gage. This round accelerates enrollment, moves the Katana system toward regulatory submission, and fuels development of NavIQ, the AI planning software converting CT angiograms into 3D models that give physicians the vascular roadmap they always wanted.
There is a business lesson here. Capital follows precision, and Akura Medical has operated with the kind of discipline that keeps investors close across multiple rounds. Returning backers alongside QIA are not reacting to noise; they are responding to a company that understands scale, understands its market, and understands that solving a condition this lethal requires clarity in every decision. With commercial ambitions set for 2026 and a VTE market still underserved, Akura Medical is stepping into a space ready for leadership rather than spectatorship.
Startups Startup Funding Venture Capital Series C AI MedTech Medical Devices Healthcare Healthcare AI Health Tech Technology Innovation Tech Ecosystem Startup Ecosystem
